Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Collplant Holdings ( (CLGN) ) is now available.
On September 15, 2025, CollPlant Biotechnologies announced the expansion of its European distribution network for its VergenixSTR product by signing a new agreement in Poland. VergenixSTR, a soft tissue repair matrix designed to treat tendinopathy, combines rhCollagen with platelet-rich plasma to promote tendon healing. This expansion is part of CollPlant’s strategy to broaden its global distribution network, enhancing its market presence in Europe and the Asia-Pacific region.
The most recent analyst rating on (CLGN) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Collplant Holdings stock, see the CLGN Stock Forecast page.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Neutral.
Collplant Holdings’ overall stock score is primarily impacted by its poor financial performance, characterized by significant revenue and cash flow declines and negative profit margins. Technical analysis provides a neutral outlook, while valuation metrics indicate potential overvaluation due to negative earnings. The lack of earnings call and corporate events data limits further insights.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative technologies and products based on non-animal-derived collagen for tissue regeneration and medical aesthetics. The company’s products, which include 3D bioprinting of tissues and organs, are based on its proprietary rhCollagen technology, addressing various fields such as tissue repair, aesthetics, and organ manufacturing.
Average Trading Volume: 55,542
Technical Sentiment Signal: Sell
Current Market Cap: $33.32M
For a thorough assessment of CLGN stock, go to TipRanks’ Stock Analysis page.